A. Sartore-Bianchi

treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients

Microbiome alterations in mismatch-repair deficient metastatic colorectal cancer patients

Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. Many efforts have been made to stratify CRC cases, from investigating the genomic characteristics of the tumor to – more recently – considering the gut microbiome. Differences in the composition of the gut microbiome occur along...

Circulating tumor DNA tumor fraction as a biomarker in refractory metastatic colorectal cancer: findings from the CAVE-2 GOIM trial

Liquid biopsy guided anti-EGFR rechallenge therapy is gaining ground as a potential option for patient with refractory metastatic colorectal cancer. However, the identification of potential biomarkers to implement patient's stratification is required. The CAVE-2 GOIM trial investigated the role of rechallenge with cetu...

Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies

In cetuximab–avelumab therapy, the absence of liver metastases and longer anti-EGFR-free interval might represent potential biomarkers and single-agent cetuximab activity is not influenced by clinical factors.